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Previewsdescribed here opens new therapeutic
possibilities for ATL treatment. Targeting
Polycomb activity, restoring the tumor
suppressor miR-31, or inhibiting NIK are
all attractive potential strategies for elimi-
nating ATL tumor cells. Furthermore, the
described involvement of miR-31 in
breast cancer cells (Valastyan et al.,
2009) raises the question of whether
miR-31 silencing through PRC2 occurs
in other type of tumors and whether these
pathways could be also be targets for
molecular therapies in those malignan-
cies. Finally, from a basic biology view-
point, the novel mechanism described
by Yamagishi et al. (2012) might have
a wider role in normal cells, given the
ubiquitous roles of NF-kB, Polycomb,
and miRNAs in several tissues.REFERENCES
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In a recent paper, Poulikakos et al. describe a new and potentially commonmechanismwhereby melanomas
develop resistance to the BRAF inhibitor vemurafenib by expressing truncated forms of BRAF(V600E) that
can dimerize in the absence of activated RAS. Will it be possible to block this with improved BRAF inhibitor
design?Metastatic melanoma has long been
renowned for being extremely difficult to
treat effectively. However, the last few
years have witnessed dramatic changes
to the landscape of this disease. In 2002,
it was discovered that over 50% of mela-
nomas harbor activating mutations, most
commonly V600E, in the gene encoding
the protein kinase BRAF, which lead to
constitutive activation of the RAF/MEK/
ERK pro-proliferative signaling pathway
(Davies et al., 2002). Within a few years,
the first selective BRAF inhibitor was in
clinical trials producing highly encour-
aging results. In a phase I clinical trial,
the BRAF(V600E) selective inhibitor ve-
murafenib (PLX4032) resulted in complete
or partial regression in the majority of
melanoma patients harboring the
BRAF(V600E) mutation (Flaherty et al.,2010). However, the excitement from
this spectacular result was soon tem-
pered as resistance to the therapy quickly
developed, resulting in response dura-
tions of only 2 to 18 months.
Vemurafenib is only effective in BRAF
mutant cells. In normal tissues and in cells
where the RAF/MEK/ERK pathway is acti-
vated by mutation of the upstream RAS
signaling proteins, vemurafenib actually
enhances signaling. Key to understanding
this surprising result is the fact that RAF
isoforms BRAF and CRAF normally
homo- or heterodimerize following activa-
tion of RAS proteins. RAF inhibitor binding
appears to cause a conformational
change that promotes the formation of
BRAF-CRAF or CRAF-CRAF dimers in
which the drug-inactivated molecule is
able to induce activation of its drug-freepartner within the dimer. On the other
hand, in cells harboring BRAF(V600E),
the levels of activated RAS (GTP bound)
are insufficient to induce dimer formation,
so BRAF(V600E) signals only as a mono-
mer and the inhibitor can completely
block its kinase activity (Hatzivassiliou
et al., 2010; Heidorn et al., 2010; Poulika-
kos et al., 2010) (Figure 1).
This model suggests that molecular
lesions that enhance RAF dimerization in
tumor cells will increase RAF activity
upon drug treatment and promote tumor
resistance. Poulikakos et al. 2011 have
now found evidence for the operation of
just such a mechanism in vemurafenib-
resistant, BRAF(V600E) mutant mela-
noma cell lines, and patient samples.
The authors generated resistant cell lines
by exposing a BRAF(V600E) melanoma21, January 17, 2012 ª2012 Elsevier Inc. 7
Figure 1. Effects of RAF Inhibitors on Cells with BRAF or RAS Mutations
Active GTP-bound RAS promotes the formation of homo- and heterodimers, but BRAF(V600E) signals
primarily as a monomer in BRAF(V600E) mutant cells because the levels of RAS-GTP are low. In contrast,
the BRAF(V600E) splice variant p61BRAF(V600E) lacks domains necessary for RAS interaction and for
preventing RAS-independent dimerization. When melanoma cells are treated with a BRAF inhibitor,
BRAF(V600E) is inhibited, leading to tumor regression. However, when RAF isoforms form dimers, either
due to RAS mutation or BRAF truncation, the drug-inactivated kinase subunit induces the transactivation
of the drug-free kinase subunit in the dimmer, resulting in continued activation of downstream pro-prolif-
erative signaling.
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In three of five resistant clones obtained,
they detected a smaller BRAF transcript
that contained both the V600E mutation
and an in-frame deletion of exons 4–8, re-
sulting in expression of a BRAF variant
lacking domains necessary for interaction
with RAS. This deletion also removes
sequences that inhibit BRAF dimerization
in the absence of RAS binding, allowing
dimerization of this variant in a RAS-inde-
pendent manner. Thus, this truncation
results in a constitutively activated
BRAF(V600E) dimer rather than the
BRAF(V600E) monomer found in the par-
ental cells. The dimer displays the trans-
activation of the drug-free subunit by the
drug-bound subunit that has been
observed for other RAF dimers (Hatzivas-
siliou et al., 2010; Heidorn et al., 2010;8 Cancer Cell 21, January 17, 2012 ª2012 ElPoulikakos et al., 2010), reducing sensi-
tivity to vemurafenib by 100-fold.
Acknowledging that generation of resis-
tant cell linesbydrugexposure in vitromay
have its limitations, Poulikakos et al. 2011
went on to demonstrate the importance of
this resistance mechanism in the clinic.
The authors analyzed tumors from 19
BRAF(V600E) mutant melanoma patients
with acquired resistance to vemurafenib
and identified a total of four shorter BRAF
transcript variants in 6 of them. All these
splicing variants lack minimally exons
4–8, one of which was identical to that
seen in the cell lines. As yet, it is unclear
how these variants were generated: could
they be caused by mutations at the splice
junctions or perhaps epigenetic changes?
This BRAF inhibitor resistance mecha-
nism is the first identified that involvessevier Inc.a structural change in BRAF itself,
bringing BRAFmore in linewith resistance
mechanisms commonly seen when phar-
macologically targeting other oncogenes,
such as activated EGFR or BCR-ABL.
Several other mechanisms of resistance
to RAF inhibitors have been previously re-
ported, but in each study, only a very
small group of tumor samples has been
analyzed, making it hard to assess their
relative importance in the clinic. Poulika-
kos et al. 2011 have analyzed the largest
cohort of tumor samples thus far, with
19 patients, of which 6 had BRAF splice
variants and 4 had mutations in NRAS,
suggesting that both BRAF and NRAS
mutations are likely to play major roles in
the development of resistance. A muta-
tion in NRAS had previously been identi-
fied as a resistance mechanism (Nazarian
et al., 2010). Other possibly rarer molec-
ular events reported previously that may
also reactivate RAF/MEK/ERK signaling
include enhancement of MAP3K8 (Cot1/
Tpl2) mRNA levels (Johannessen et al.,
2010) and an activating mutation in
MEK1 (Wagle et al., 2011). Alterations
that activate PI3K pathway signaling,
including increased expression of
PDGFRb or IGF-1R levels or deletion of
PTEN, have also been detected (Nazarian
et al., 2010).
Drug resistance is arguably the biggest
challenge blocking progress toward
better outcomes in cancer treatment.
Obviously, the importance of identifying
drug resistance mechanisms lies in the
possibility of developing better drugs or
drug combinations to overcome resis-
tance. For BRAF mutant melanoma,
many resistance mechanisms result in
ERK pathway reactivation, suggesting
that inhibition of the pathway down-
stream of RAF using MEK inhibitors
could overcome acquired resistance
and might also have value in combination
with vemurafenib to limit the develop-
ment of resistance. However, MEK inhib-
itors have yet to prove their worth in
the clinic. Perhaps a more interesting
approach to tackling resistance is the
development of new RAF inhibitors. The
ideal drug would be one that was
specific for oncogenic BRAF but would
not transactivate CRAF or truncated
BRAF, but achieving this may be quite
a challenge for drug developers. Existing
BRAF inhibitors also have some activity
toward CRAF, and it is possible that
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Previewsthe transactivation has actually been
selected in the drug development pro-
cess because it circumvents potential
systemic toxicity associated with pan-
RAF inhibition.
Vemurafenib resistance often develops
rapidly and multiple resistant tumor
nodules usually appear at the same time
(Wagle et al., 2011). The efficacy of RAF
inhibitors depend on almost complete
inhibition of ERK signaling; partial RAF
inhibition or small changes that increase
pathway activity can produce resistance.
One possible reason for the rapid simul-
taneous appearance of resistant nodules
is the existence of minor populations of
resistant cells in the original tumors prior
to treatment that can overtake the drug-
sensitive populations. If this is the case,
emergence of a single resistance mecha-
nism should be seen if several different
resistant lesions from the same patient
are analyzed. More worrying is the possi-
bility that tumor cells can escape
destruction via any of a plethora of
relatively easily accessed routes, so
that each different resistant lesion in
a patient is using a different mechanism.
It has been suggested that tumor
heterogeneity and changes in drugresponse can be mediated by epigenetic
changes (Sharma et al., 2010), leading to
changes in expression of some genes
and potentially splicing alterations. This
suggests that combination treatment
with epigenetic modulators such as
histone deacetylase inhibitors could be
tested to overcome RAF inhibitor-medi-
ated resistance.
The extremely rapid progress in under-
standing BRAF inhibitor resistance mech-
anisms raises hopes that the partial
success of targeted agents like vemurafe-
nib may soon lead to more lasting patient
benefit. However, the complexity seen in
the BRAF signaling network response to
these drugs and the ease with which
tumors develop resistance to them
suggests that there will be many more
unexpected twists to this story before
metastatic melanoma can be considered
beaten.
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